The ethics of placebo and risk in children’s trials
Children cannot fully consent, so research rules ask more of the people designing paediatric trials. Placebo arms are where those rules bite hardest.
In brief
When is a placebo arm ethical in a children’s trial? ICH E11, risk limits, consent and assent, and the trial designs that reduce placebo exposure.
Every clinical trial involves a judgement that the knowledge gained justifies the risks to participants. In paediatric research that judgement is made on behalf of people who cannot fully weigh it themselves, and the rules reflect that.
The framework
The ICH E11 guideline on clinical investigation of medicinal products in the paediatric population, adopted in 2000 and updated with an addendum in 2017, is the international reference point. It accepts that children need medicines studied in them, while setting expectations for minimising risk, discomfort and the number of children enrolled.
In the US, federal regulations add specific categories for research involving children. Research that offers no prospect of direct benefit is generally limited to minimal risk, or a minor increase over minimal risk under specific conditions.
When placebo is acceptable
Placebo-controlled trials give the clearest answers about efficacy. They are ethically straightforward when no proven treatment exists. They are much harder to justify when an effective treatment is available and withholding it could cause serious or irreversible harm.
Common ways designers manage the tension include:
- Add-on designs, where all children receive standard treatment and the new drug or placebo is added on top.
- Short placebo periods with clear rescue criteria.
- Randomised withdrawal, where all children start on the drug and only those who respond are randomised to continue or switch.
- Extrapolation, which can remove the need for a paediatric efficacy comparison altogether.
Consent, assent and dissent
Parents give permission, but children who can understand are asked to agree, and their refusal is generally respected in research that offers them no direct benefit. Explaining a trial to a seven-year-old and to a fifteen-year-old are very different tasks, and good studies prepare age-appropriate materials for both.
